Bitget App
Trade smarter
Acheter des cryptosMarchésTradingFuturesEarnCommunautéPlus
Prix
Données
À propos
NTRA stock price forecast
Actualités
Concurrents
Tokenisation
Crypto
FAQ
Logo action Natera, Inc.

Natera, Inc.

NTRA·NASDAQ

Dernière mise à jour : 2026-02-13 14:56 EST. Les données sur les prix des actions proviennent de TradingView et reflètent les prix du marché en temps réel.

Insights
Calculateur
Actualités

Variation du cours des actions NTRA

Le dernier jour de trading, l'action NTRA a clôturé à 210.40 USD, avec une variation de prix de -0.97% pour la journée.
Trader des Futures sur actions

À propos de Bitget

La première plateforme d'échange (UEX) au monde, permettant aux utilisateurs de trader non seulement des cryptomonnaies, mais aussi des actions, des ETF, le Forex, l'or et des actifs du monde réel (RWA).
En savoir plus

NTRA – Données clés

Clôture précédente210.40 USD
Capitalisation29.10B USD
Volume118.25K
Ratio P/E-
Rendement du dividende (sur 12 mois)0.00%
Montant du dividende-
Dernière date de détachement-
Date du dernier paiement-
BPA dilué (sur 12 mois)-2.28 USD
Résultat net (ex. financier)−190.43M USD
Chiffre d'affaires (ex. financier)1.70B USD
Date du prochain rapportMar 4, 2026
Estimation du BPA-
Chiffre d'affaires estimé604.04M USD USD
Actions en circulation131.67M
Bêta (1Y)0.90
Tokenized stocks

Avez-vous déjà entendu parler des actions tokenisées ?

Une nouvelle façon de trader des actions – n'importe où, 24h/7j

En savoir plus

Natera, Inc. – Vue d'ensemble

Natera, Inc. est une société de diagnostic spécialisée dans la découverte, le développement et la commercialisation de services de tests génétiques. Elle propose le test prénatal non invasif Panorama (NIPT), Vistara, le dépistage des porteurs Horizon (HCS), le dépistage génétique pré-implantatoire Spectrum et le diagnostic génétique pré-implantatoire Spectrum, les produits Anora pour l’analyse des produits de conception (POC) et le test de paternité non invasif (PAT). L’entreprise a été fondée par Matthew Rabinowitz et Jonathan Sheena en novembre 2003 et son siège social est situé à Austin, Texas.
Secteur
Technologie de la santé
Secteur d'activité
Biotechnologie
CEO
Stephen Leonard Chapman
Siège social
Austin
Site web
natera.com
Création
2003
Employés (ex. financier)
4.43K
Variation (1 an)
+1.14K +34.65%
Chiffre d'affaires / Employé (1Y)
382.70K USD
Résultat net / Employé (1Y)
−42.95K USD

Baromètre NTRA en temps réel

Daily updates on NTRA stock prices, fund flows, and market news, generated by AI and reviewed by our team of analysts. Always DYOR.

• Variation du cours de l'action NTRA sur 24h : +0,38 %. De 211,65 USD à 212,46 USD.
• D'un point de vue technique, NTRA se trouve actuellement dans une « phase de reprise à court terme » : la moyenne mobile sur 50 jours (231,82 $) se situe au-dessus du cours actuel, agissant comme une résistance, tandis que l'action reste nettement au-dessus de sa moyenne mobile sur 200 jours (198,09 $), ce qui indique que la tendance haussière de long terme demeure intacte. Les récentes conditions de survente (RSI proche de 40 la semaine dernière) ont déclenché un rebond modéré, mais le signal quotidien « Forte Vente » issu des moyennes mobiles invite à la prudence alors que le marché digère d'importantes ventes d'initiés.
• Le PDG de Natera, Steven Chapman, et le directeur financier, Michael Brophy, ont vendu pour un total de 22 millions de dollars d'actions début février dans le cadre de plans préétablis 10b5-1, contribuant à la récente volatilité et à une baisse de 15 % sur une période de 9 jours.
• L'entreprise a soumis une demande de Premarket Approval (PMA) à la FDA pour son test Signatera CDx en tant que diagnostic compagnon pour le cancer de la vessie musculaire invasive, une étape majeure dans son expansion en oncologie.
• Natera a annoncé une croissance préliminaire de son chiffre d'affaires au T4 2025 de près de 40 % en glissement annuel, dépassant largement les attentes des analystes et maintenant des recommandations « Surperformance » de la part de grands courtiers comme Piper Sandler et Morgan Stanley.
• BridgeBio Pharma a annoncé le succès d'un essai de phase 3 pour son médicament contre l'achondroplasie, tandis que Lundbeck a rapporté des résultats positifs pour un essai préventif contre la migraine, soulignant une période de publications de données cliniques majeures pour le secteur biotechnologique.
• Icon plc a retiré ses prévisions financières pour 2025 et lancé une enquête comptable interne, suscitant la prudence dans l'industrie de la recherche médicale et des services cliniques.
Voir plus
il y a 1j
• Variation du cours de l'action NTRA sur 24h : -2,79 %. De 211,66 USD à 205,75 USD. Ce repli s'explique principalement par la réaction persistante des investisseurs face à d'importantes ventes d'actions par le PDG et d'autres dirigeants, ainsi que par une phase d'ajustement plus large du marché dans le secteur du diagnostic médical. • D'un point de vue technique, le titre évolue actuellement dans une « phase baissière à court terme au sein d'une tendance haussière à long terme » : il se négocie sous ses moyennes mobiles à 20 jours (231,27) et 50 jours (233,64), mais reste au-dessus de la moyenne mobile à 200 jours (184,08). Le RSI est proche de 30, indiquant que l'action approche de la zone de survente, ce qui pourrait entraîner un rebond technique autour du support des 200 dollars. • Le PDG de Natera, Steven Leonard Chapman, et d'autres initiés ont déclaré avoir vendu pour plus de 20 millions de dollars d'actions début février 2026, dans le cadre de plans de trading préétablis 10b5-1. • Natera a annoncé le dépôt d'une demande de Premarket Approval (PMA) auprès de la FDA pour son test Signatera CDx, destiné à détecter la maladie résiduelle moléculaire (MRD) chez les patients atteints d'un cancer de la vessie. • L'entreprise a terminé l'inclusion des patients dans son essai randomisé ACES-EMB, évaluant le test Prospera Heart comme alternative non invasive aux biopsies de routine chez les receveurs de greffe cardiaque. • Le gouvernement britannique a lancé le National HealthTech Access Programme afin d'accélérer l'adoption de diagnostics innovants du cancer et d'outils d'IA dans l'ensemble du système de santé. • Les projections du marché mondial du diagnostic digital anticipent un taux de croissance annuel composé de 18,3 %, pour atteindre 8,6 milliards de dollars d'ici 2033, porté par l'intégration de l'IA et la demande croissante en médecine de précision.
Voir plus
il y a 2j

NTRA stock price forecast

According to technical indicators for NTRA stock, the price is likely to fluctuate within the range of 245.77–253.88 USD over the next week. Market analysts predict that the price of NTRA stock will likely fluctuate within the range of 217.21–254.06 USD over the next months.

Based on 1-year price forecasts from 63 analysts, the highest estimate is 300.38 USD, while the lowest estimate is 209.67 USD.

For more information, please see the NTRA stock price forecast Stock Price Forecast page.

Avec un simple compte Bitget, vous pouvez trader simultanément des actions et des cryptomonnaies.

Participer maintenant

FAQ

Quel est le cours de l'action Natera, Inc. ?

NTRA a actuellement un prix de 210.40 USD. Son cours a varié de -0.97% au cours des dernières 24h. Vous pouvez suivre de plus près l'évolution du cours de l'action Natera, Inc. sur le graphique de prix en haut de cette page.

Quel est le symbole boursier de Natera, Inc. ?

Selon la plateforme, le symbole boursier peut varier. Par exemple, sur NASDAQ, Natera, Inc. est tradé sous le symbole NTRA.

Quelles sont les prévisions pour les actions NTRA ?

Nous avons recueilli des avis d'analystes sur le cours futur de Natera, Inc.. Selon leurs prévisions, NTRA a une estimation maximale de 2104.00 USD et une estimation minimale de 420.80 USD.

Quelle est la capitalisation boursière de Natera, Inc. ?

Natera, Inc. a une capitalisation boursière de 29.10B USD.

What is P/E ratio (TTM)?

The P/E ratio (TTM) stands for price-to-earnings ratio (trailing twelve months). It is a historical valuation metric calculated using a company's earnings per share (EPS) over the most recent twelve consecutive months, reflecting the company's past profitability.

The P/E ratio measures the relationship between a stock's price and a company's profitability, and is often used as a basis for judging whether a stock is "cheap" or "expensive."

P/E ratio = market price (P) ÷ earnings per share (EPS), or P/E ratio = total market capitalization ÷ net profit attributable to shareholders

The interpretation of the P/E ratio (TTM) should always be considered alongside other factors and is mainly used for valuation comparisons rather than as a standalone indicator.

  • A lower P/E ratio (TTM) means investors are paying less for each unit of earnings. This may indicate that the stock is undervalued, or that the market has limited expectations for the company's future growth, such as in mature or slow-growing industries.
  • A higher P/E ratio (TTM) means investors are paying more for each unit of earnings. This often reflects expectations of strong future earnings growth, which is common among growth or technology stocks, though it may also suggest the stock is overvalued.
  • Comparison with peers: Compare the company's P/E (TTM) with the average or median P/E of other companies in the same industry. A significantly higher P/E may require further analysis to determine whether the company's high valuation is justified by stronger growth prospects or competitive advantages.
  • Comparison with historical levels: Compare the company's current P/E (TTM) with its own historical average (such as over the past 5 or 10 years) to assess whether the current valuation is at a historical high or low.
  • Comparison with the broader market: Compare the company's P/E (TTM) with major market indices (such as the S&P 500) to see how the market is valuing the company overall.

P/E ratios can vary widely across industries, and there is no single "ideal" P/E level. A reasonable P/E range depends on the industry, the company's growth potential, and the broader macroeconomic environment. Investment decisions should not rely solely on the P/E ratio (TTM) but should be based on a comprehensive analysis that includes company quality, growth prospects, and financial health.

Can I trade stocks on Bitget?

You can trade stocks on Bitget, but mainly through stock tokens and stock perps, rather than by directly buying or selling traditional stocks.

This approach reflects Bitget's vision as a Universal Exchange (UEX), designed to connect traditional financial markets with cryptocurrency markets.

Bitget currently offers the following stock-related trading formats:

1. Stock tokens (spot)

Nature: Stock tokens are digital tokens pegged to the price of specific traditional stocks (such as TSLAUSDT and NVDAUSDT) and are traded on Bitget's spot market.

Features: When you trade stock tokens, you are buying and holding tokens rather than owning the underlying traditional stocks.

  • The price of these tokens generally follows the price movements of the stocks they are pegged to, such as Tesla or Nvidia.
  • The advantage is that you can participate in the price movements of traditional financial assets, such as U.S. stocks, using cryptocurrencies (for example, USDT), without the need for a traditional brokerage account.

2. Stock perps

Nature: Bitget also offers USDT-margined perpetual futures, commonly referred to as stock perps, based on major U.S. blue-chip stocks such as Tesla and Meta.

Characteristics: Stock perps are derivative products that allow you to take a bullish or bearish view on the future price of an underlying stock through margin trading. These products typically support leverage, such as up to 25x.

It does not involve owning the underlying stock. Instead, profits and losses are settled based on price movements of the futures.

Important note: When trading stock perps on Bitget, you are participating in derivative markets within the cryptocurrency ecosystem. This is fundamentally different from purchasing publicly traded shares through a traditional brokerage, as you do not own equity in the underlying company.

Futures trading and the use of leverage involve high risk. Please ensure you fully understand the risks before trading.

If you wish to directly hold equity in traditional stocks and enjoy shareholder rights (such as receiving dividends), you must trade through a regulated traditional securities brokerage or brokerage platform.

What are the advantages of Bitget's stock perps?

Bitget's stock perps—typically perpetual futures based on stock tokens prices—are an innovative offering that allows cryptocurrency platforms to provide exposure to traditional financial markets.

Compared to traditional stock or futures trading, they offer several unique advantages, primarily due to the platform's trading infrastructure.

Bitget's stock perps, typically USDT-denominated derivatives, offer the following key advantages:

1. Trading convenience and global accessibility

  • 24/7 trading: Traditional stock markets, such as U.S. equity markets, operate during fixed trading hours. In contrast, cryptocurrency derivatives markets are typically open 24/7. This means investors can trade anytime, capitalizing on breaking news or market fluctuations.
  • Lower entry barriers and faster onboarding: Compared with traditional brokerages, which often require extensive identity verification and lengthy account setup processes, Bitget generally offers faster account onboarding. Users can trade using cryptocurrencies such as USDT, without the need for complex fiat deposit and withdrawal procedures.
  • Global accessibility: Users can access derivatives trading linked to globally recognized stocks via the Bitget platform, subject to applicable regulations.

2. Capital efficiency and high leverage

  • High leverage options: Stock perps typically offer higher leverage than traditional stock trading (for example, up to 25x). This allows traders to control larger positions with smaller margin requirements, improving capital efficiency.
    Note: While high leverage can amplify gains, it also amplifies losses proportionally.
  • Two-way trading: Traders can easily take both long and short positions. This means traders can potentially profit from market volatility whether stock prices rise or fall, provided the market direction is correctly anticipated.

3. Trading and settlement using cryptocurrency

  • USDT margin: Stock perps on Bitget typically use USDT (or other stablecoins) as the margin and settlement currency. For users who already hold cryptocurrency, there is no need to convert assets into fiat currency, allowing them to trade directly with stablecoins.
  • Efficient fund transfers: Crypto-based transfers and settlements are typically faster than traditional fiat systems, enabling more efficient global fund allocation.

4. Integration

One-stop platform: Bitget allows users to trade spot cryptocurrencies, crypto derivatives, and stock perps on a single platform, making it easier to manage different asset types in one place.

Avertissement sur les risques:

While Bitget's stock perps offer several advantages, it is important to understand the associated risks.

  • High leverage risk: Leveraged trading can result in rapid loss of your entire margin.
  • No equity ownership: When trading stock perps, you do not own the underlying shares. As a result, you are not entitled to dividends or voting rights.
  • Market liquidity risk: Tokenized stock perps may have lower liquidity than their counterparts in traditional stock markets, especially outside regular trading hours.

In summary, Bitget's stock perps offer advantages such as greater trading flexibility, lower entry barriers, and higher capital efficiency.

What are the trading fees for Bitget stock perps?

Trading fees for Bitget stock perps (USDT-margined perpetual futures) mainly include transaction fees and funding rates.

Transaction fees:

Bitget offers limited-time fee promotions for stock perps (especially tokenized stock perps) from time to time to attract traders.

Standard reference rates: Under Bitget's standard futures fee structure, the taker fee is typically around 0.06%, while the maker fee is around 0.02%.

Current promotions for stock perps (important): To promote its stock perps products, Bitget is offering discounted transaction fees during Q4 2025, with taker fees as low as 0.006% and maker fees as low as 0.002%. There is also a limited-time promotion offering zero-fee trading for spot stock tokens.

Recommandation : les activités promotionnelles pouvant être modifiées ou interrompues à tout moment, veuillez consulter les pages officielles " Fee overview " ou " Announcement Center " de Bitget pour connaître les taux les plus récents et les plus précis au moment du trading.

Funding rate:

The funding rate is a key mechanism in perpetual futures (including stock perps) that helps keep the futures price closely aligned with the spot price of the underlying asset. It is not a fee charged by the platform, but a periodic payment exchanged between long and short traders.

Funding rates fluctuate dynamically and are mainly driven by market sentiment and imbalances between long and short positions. Stock perps generally experience lower volatility than cryptocurrencies, so funding rates are often relatively low during stable market conditions. However, during earnings seasons or major positive or negative news events, heavy concentration of long or short positions—such as in high-growth technology stocks like Tesla or Nvidia—can create significant imbalances, causing funding rates to spike in the short term.

Funding payments are typically settled every 8 hours. If you close your position before the funding settlement time, no funding payment will be charged or received.

Funding rates are not fixed. If you hold a position for an extended period, high positive funding rates (for long positions) or high negative funding rates (for short positions) will affect your overall holding costs or potential returns. For this reason, it is important to monitor the funding rate in real time on the trading interface.

NASDAQ/
NTRA
Bitget© 2026